Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Autolus Therapeutics plcNASDAQ: AUTL
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -227.0%
Operating margin was -227.0% in Q1 FY2026, up 499.3 pp from a year earlier. On a trailing-twelve-month basis it was -285.9%, up 4535.6 pp year over year. Over 3 fiscal years it widened by 1934.5 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 6 analysts of -119.2% for the fiscal year ending Dec 2026, up from -372.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -227.0%+71.4 pp QoQ
- Last fiscal yearDec 2025
- -372.4%+2013.2 pp YoY
- LTMMar 2026
- -285.9%+4535.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -372.4%
- Year-over-year change
- +2013.2pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -372.4% | +2013.2pp |
| FY2024 | 2024-12-31 | -2385.6% | +8197.5pp |
| FY2023 | 2023-12-31 | -10583.1% | -8276.1pp |
| FY2022 | 2022-12-31 | -2307.0% | +7007.8pp |
| FY2021 | 2021-12-31 | -9314.8% | — |
Operating Margin vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 operating margin of -285.9% is the 6th highest of the 9 companies compared; the peer median is -77.2%.
- Its year-over-year change of +4535.6 pp is the highest of 9, against a peer median of +11.4 pp.
- Over three fiscal years its change of +1934.5 pp compares with a peer median of +236.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 2.5% | +23.5 pp | +376.1 pp | |
| FY2025 | -13.8% | +2082.7 pp | +2560.4 pp | |
| LTM Mar 2026 | -27.3% | -20.6 pp | +470.9 pp | |
| LTM Mar 2026 | -67.6% | +43.4 pp | +422.4 pp | |
| LTM Mar 2026 | -86.8% | -0.6 pp | +96.1 pp | |
| LTM Mar 2026 | -285.9% | +4535.6 pp | +1934.5 pp | |
| LTM Mar 2026 | -1175.7% | +473.1 pp | -452.3 pp | |
| LTM Mar 2026 | -2207.5% | -704.0 pp | -1902.2 pp | |
| LTM Mar 2026 | -618909.7% | -64222.0 pp | -565818.0 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding AUTL) | -77.2% | +11.4 pp | +236.1 pp | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M |
| Cost of Revenue | 0 | 0 | 0 | 141.02M | 96.59M |
| Gross Profit | 1.51M | 6.19M | 1.7M | (130.9M) | (21.03M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| Research & Development | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M |
| Selling, General & Admin | 31.87M | 31.9M | 46.75M | 0 | 131.82M |
| Operating Expenses | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M |
| EBITDA | (132.48M) | (132.24M) | (156.77M) | (233.07M) | (250.26M) |
| EBITDA Margin | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% |
| Operating Income | (140.37M) | (142.89M) | (179.7M) | (241.43M) | (281.44M) |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Income | 262K | 1.71M | 13.51M | 32.36M | 19.02M |
| Interest Expense | 1.11M | 8.91M | 45.07M | 9.29M | 36.76M |
| Other Income / Expenses | (1.66M) | (5.67M) | (28.7M) | 22.29M | (15.41M) |
| Income Before Tax | (142.04M) | (148.57M) | (208.4M) | (219.13M) | (296.85M) |
| Pre-Tax Margin | -9425.2% | -2398.6% | -12273.4% | -2165.4% | -392.8% |
| Income Tax Expense | 58K | 272K | (19K) | 1.53M | (8.65M) |
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (288.2M) |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (Basic) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| EPS (Diluted) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| Weighted Avg Shares | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Weighted Avg Shares (Diluted) | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.